


## DS-1971a

<b>Cat. No.:</b>	HY-131182		
<b>CAS No.:</b>	1450595-86-4		
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>21</sub> ClFN <sub>5</sub> O <sub>3</sub> S		
<b>Molecular Weight:</b>	465.93		
<b>Target:</b>	Sodium Channel		
<b>Pathway:</b>	Membrane Transporter/Ion Channel		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (214.62 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	2.1462 mL	10.7312 mL	21.4625 mL
		5 mM	0.4292 mL	2.1462 mL	4.2925 mL
10 mM		0.2146 mL	1.0731 mL	2.1462 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (5.37 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.37 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (5.37 mM); Clear solution</li> </ol>				

### BIOLOGICAL ACTIVITY

<b>Description</b>	DS-1971a is a potent, selective, and orally active NaV1.7 inhibitor, with IC <sub>50</sub> s of 22.8 and 59.4 nM for hNaV1.7 and mNaV1.7, respectively. DS-1971a exerts analgesic effects <sup>[1]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	hNa <sub>v</sub> 1.7 22.8 nM (IC <sub>50</sub> )	mNa <sub>v</sub> 1.7 59.4 nM (IC <sub>50</sub> )
<b>In Vivo</b>	DS-1971a exhibits a favorable toxicological profile <sup>[1]</sup> .	

DS-1971a (0.1-1 mg/kg; p.o.) shows mitigated thermal hyperalgesia in a dose-dependent manner in partial sciatic nerve ligation (PSL) mice<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Slc:ddY mice (PSL model) <sup>[1]</sup>
Dosage:	0.1, 0.3, and 1 mg/kg
Administration:	P.o.
Result:	A significant dose-dependent suppression of thermal hyperalgesia in 0.3 and 1 mg/kg administered groups. The ED <sub>50</sub> of DS-1971a at the peak efficacy was 0.32 mg/kg.

## REFERENCES

[1]. Shinozuka T, et al. Discovery of DS-1971a, a Potent, Selective NaV1.7 Inhibitor [published online ahead of print, 2020 May 26]. J Med Chem. 2020;10.1021/acs.jmedchem.0c00259.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA